Company intelligence / Profile preview
VasGene Therapeutics, Inc.
Los Angeles/Oak Park*, California, USAvasgene.com ↗
- Ownership
- Private
- Employees
- ~5
- Development stage
- Other
01
Overview
VasGene Therapeutics specializes in vascular biology-based therapeutics targeting signal transduction pathways shared by cancer and endothelial cells. Its lead candidate, sEphB4-HSA, has advanced to Phase II/III clinical trials for metastatic urothelial carcinoma and has shown signs of clinical benefit with no dose-limiting toxicities observed in early trials. Several other programs have been discontinued.[1][3]
Preclinical and early clinical data indicate stable disease and some tumor regression in patients treated with sEphB4-HSA; further studies are ongoing or planned.[3]- Therapeutic areas
- OphthalmologyOncology
- Modalities
- Biological productsFusion proteinsHumanized monoclonal antibodies (mAbs)
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Beyond the preview
Go deeper on VasGene Therapeutics, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VasGene Therapeutics, Inc..